Comparison · NCT03013491-c6cf674b
CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy. Trial comparisons, record NCT03013491-c6cf674b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03013491-c6cf674b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0625 | 0.0111 | 0.283 | wilson | |
| Risk in group 2 | 0.133 | 0.0792 | 0.214 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0702 | -0.166 | 0.157 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.471 | 0.0661 | 3.36 | log | |
| Odds ratio, group 1 over group 2 | 0.436 | 0.053 | 3.58 | log | |
| Number needed to treat, for one fewer participant with the outcome on CX-072 10 mg/kg (Part A and Part A2) than on CX-072 10 mg/kg (Part D) | 14.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CX-072 10 mg/kg (Part A and Part A2) | Monotherapy CX-072 10 mg/kg (Part A and Part A2)~CX-072: Solution for infusion | 1 | 16 | OG000 |
| Group 2 | CX-072 10 mg/kg (Part D) | Monotherapy CX-072 10 mg/kg expansion | 13 | 98 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy
- Description
- The primary efficacy endpoint, ORR, was defined as the proportion of subjects with complete response (CR) or partial response (PR) on two consecutive tumor assessments according to RECIST v1.1.
- Time frame
- 2 years
- Population
Per CX-072-001 Statistical Analysis Plan, efficacy analyses will be limited to subjects who received 10 mg/kg CX-072 as monotherapy during the study. This efficacy subset includes subjects from Parts A, A2 and D. Efficacy summaries will have parts A and A2 combined
Source ClinicalTrials.gov
Trial
- Title
- PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- NCT number
- NCT03013491
- Phases
- PHASE1, PHASE2
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- CX-072, ipilimumab, vemurafenib
- Lead sponsor
- CytomX Therapeutics
- Results first posted
- 2025-06-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03013491?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03013491-c6cf674b